Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Cancer vaccine strategies: translation from mice to human clinical trials.

Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, Wood LV.

Cancer Immunol Immunother. 2018 Dec;67(12):1863-1869. doi: 10.1007/s00262-017-2084-x. Epub 2017 Nov 15. Review.

PMID:
29143114
2.

Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.

Castiello L, Sabatino M, Ren J, Terabe M, Khuu H, Wood LV, Berzofsky JA, Stroncek DF.

Clin Cancer Res. 2017 Jul 1;23(13):3352-3364. doi: 10.1158/1078-0432.CCR-16-2199. Epub 2017 Jan 10.

3.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

4.

Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, Wood LV, Jarosinski PF, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7340-7346. doi: 10.1128/AAC.01427-16. Print 2016 Dec.

5.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.

Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

6.

Colon cancer metastasis to the thyroid gland: report of a case with unique molecular profile.

Roloff GW, Yang Z, Wood LV, Neychev VK.

Clin Case Rep. 2016 Apr 22;4(6):549-53. doi: 10.1002/ccr3.497. eCollection 2016 Jun.

7.

Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.

Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL.

J Nucl Med. 2016 Jun;57(6):886-92. doi: 10.2967/jnumed.115.166512. Epub 2016 Jan 21.

8.

Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.

Wang J, Shirota Y, Bayik D, Shirota H, Tross D, Gulley JL, Wood LV, Berzofsky JA, Klinman DM.

J Immunol. 2015 May 1;194(9):4215-21. doi: 10.4049/jimmunol.1402004. Epub 2015 Mar 30.

9.

Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies.

Stroncek DF, Fellowes V, Pham C, Khuu H, Fowler DH, Wood LV, Sabatino M.

J Transl Med. 2014 Sep 17;12:241. doi: 10.1186/s12967-014-0241-y.

10.

An interesterified palm olein test meal decreases early-phase postprandial lipemia compared to palm olein: a randomized controlled trial.

Hall WL, Brito MF, Huang J, Wood LV, Filippou A, Sanders TA, Berry SE.

Lipids. 2014 Sep;49(9):895-904. doi: 10.1007/s11745-014-3936-1. Epub 2014 Aug 8.

PMID:
25103522
11.

Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.

Berzofsky JA, Wood LV, Terabe M.

Expert Rev Vaccines. 2013 Oct;12(10):1115-8. doi: 10.1586/14760584.2013.836906. No abstract available.

12.

Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling.

Castiello L, Sabatino M, Zhao Y, Tumaini B, Ren J, Ping J, Wang E, Wood LV, Marincola FM, Puri RK, Stroncek DF.

Mol Ther. 2013 Feb;21(2):476-84. doi: 10.1038/mt.2012.89. Epub 2012 Nov 13. Erratum in: Mol Ther. 2013 Feb;21(2):495.

13.

Why I voted "no" to Truvada PrEP.

Wood LV.

Ann Intern Med. 2012 Oct 2;157(7):519-20. No abstract available.

PMID:
22821402
14.

Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents.

Calabrese SK, Martin S, Wolters PL, Toledo-Tamula MA, Brennan TL, Wood LV.

AIDS Care. 2012;24(9):1092-6. doi: 10.1080/09540121.2012.699670.

15.

Strategies to use immune modulators in therapeutic vaccines against cancer.

Berzofsky JA, Terabe M, Wood LV.

Semin Oncol. 2012 Jun;39(3):348-57. doi: 10.1053/j.seminoncol.2012.02.002. Review.

16.

Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

Arlen PM, Wood LV.

Expert Rev Vaccines. 2012 Mar;11(3):287-302. doi: 10.1586/erv.11.183. Review.

PMID:
22380822
17.

A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers.

Martin S, Elliott-DeSorbo DK, Calabrese S, Wolters PL, Roby G, Brennan T, Wood LV.

AIDS Patient Care STDS. 2009 Aug;23(8):593-601. doi: 10.1089/apc.2009.0021.

18.

The Antiretroviral Regimen Complexity Index. A novel method of quantifying regimen complexity.

Martin S, Wolters PL, Calabrese SK, Toledo-Tamula MA, Wood LV, Roby G, Elliott-DeSorbo DK.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):535-44.

PMID:
17589371
19.

Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents.

Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, Wood LV.

Pediatr Infect Dis J. 2007 Jan;26(1):61-7.

PMID:
17195708
21.

Could human papillomaviruses be spread through blood?

Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng ZM.

J Clin Microbiol. 2005 Nov;43(11):5428-34.

22.
23.

Assessing medication adherence in adolescents with HIV when electronic monitoring is not feasible.

Wiener L, Riekert K, Ryder C, Wood LV.

AIDS Patient Care STDS. 2004 Sep;18(9):527-38.

PMID:
15630773
24.

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.

Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S.

Pediatrics. 2004 Aug;114(2):e235-42.

PMID:
15286262
25.

Coping styles among families of children with HIV infection.

Martin SC, Wolters PL, Klaas PA, Perez L, Wood LV.

AIDS Care. 2004 Apr;16(3):283-92.

PMID:
15203422
26.

Post-surgical scleritis associated with the ganciclovir implant.

Srivastava S, Taylor P, Wood LV, Lee SS, Robinson MR.

Ophthalmic Surg Lasers Imaging. 2004 May-Jun;35(3):254-5.

PMID:
15185797
27.

Cerebrovascular disease in HIV-infected pediatric patients: neuroimaging findings.

Patsalides AD, Wood LV, Atac GK, Sandifer E, Butman JA, Patronas NJ.

AJR Am J Roentgenol. 2002 Oct;179(4):999-1003.

PMID:
12239054
28.

Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy.

Chiou CC, Groll AH, Mavrogiorgos N, Wood LV, Walsh TJ.

Pediatr Infect Dis J. 2002 May;21(5):388-92.

PMID:
12150174
29.

Burkitt's/Burkitt's-like lymphoma presenting as bacterial sinusitis in two HIV-infected children.

Robinson MR, Salit RB, Bryant-Greenwood PK, Zeichner SL, Wood LV, Jaffe ES, van Waes C, Magrath IT.

AIDS Patient Care STDS. 2001 Sep;15(9):453-8.

PMID:
11587630
30.

Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection.

Sei S, Boler AM, Nguyen GT, Stewart SK, Yang QE, Edgerly M, Wood LV, Brouwers P, Venzon DJ.

AIDS. 2001 Jul 27;15(11):1343-52.

PMID:
11504955
31.

Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma.

Sei S, O'Neill DP, Stewart SK, Yang Q, Kumagai M, Boler AM, Adde MA, Zwerski SL, Wood LV, Venzon DJ, Magrath IT.

Cancer Res. 2001 Jul 1;61(13):5028-37.

32.

A potential role for interleukin-7 in T-cell homeostasis.

Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, Landay A, Mackall CL.

Blood. 2001 May 15;97(10):2983-90.

33.

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.

Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.

J Infect Dis. 2001 Apr 1;183(7):1116-20. Epub 2001 Mar 1.

PMID:
11237839
34.

Impact of chemotherapy for AIDS-related malignancies in pediatric HIV disease.

Gonzalez CE, Adde M, Taylor P, Wood LV, Magrath I.

Ann N Y Acad Sci. 2000 Nov;918:362-6. No abstract available.

PMID:
11131726
35.

Lymphoid interstitial pneumonitis in pediatric AIDS. Natural history of the disease.

Gonzalez CE, Samakoses R, Boler AM, Hill S, Wood LV.

Ann N Y Acad Sci. 2000 Nov;918:358-61. No abstract available.

PMID:
11131724
36.

Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1.

Toro JR, Wood LV, Patel NK, Turner ML.

Arch Dermatol. 2000 Aug;136(8):983-5. No abstract available. Erratum in: Arch Dermatol 2002 Feb;138(2):257.

PMID:
10926733
37.

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases.

Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA.

Ann Intern Med. 2000 Aug 1;133(3):192-6.

PMID:
10906833
38.

Highly active antiretroviral therapy: progress and pitfalls.

Wood LV.

J Pediatr. 1999 Dec;135(6):655-7. No abstract available.

PMID:
10586162
39.

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.

Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV.

J Infect Dis. 1999 Sep;180(3):626-40.

PMID:
10438349
40.
41.

A phase I/II study of the protease inhibitor indinavir in children with HIV infection.

Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwerski S, Sei S, Wood LV, Zeichner S, Pizzo PA.

Pediatrics. 1998 Jul;102(1 Pt 1):101-9.

PMID:
9651421
42.

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.

Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Katz TT, Higham C, Aker D, Edgerly M, Jarosinski P, Serchuck L, Whitcup SM, Pizzuti D, Pizzo PA.

Pediatrics. 1998 Mar;101(3 Pt 1):335-43.

PMID:
9480994
43.

Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Thomas CR Jr, Stelzer KJ, Douglas JG, Koh WJ, Wood LV, Panicker R.

J Natl Med Assoc. 1994 Nov;86(11):839-52.

44.

Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

Thomas CR Jr, Wood LV, Douglas JG, Stelzer KJ, Koh W, Panicker R.

J Natl Med Assoc. 1994 Oct;86(10):765-74. Review.

45.

Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein.

Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, de la Cruz VF, Davey RT Jr, Venkatesan S, Moss B, et al.

J Immunol. 1990 Jul 1;145(1):127-35.

PMID:
1694201
46.

Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.

Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV.

JAMA. 1986 Feb 14;255(6):757-60.

PMID:
3944976
47.

Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans.

Morgan DR, Johnson PC, DuPont HL, Satterwhite TK, Wood LV.

Infect Immun. 1985 Oct;50(1):62-5.

48.

Evaluation of BW942C, a novel antidiarrheal agent, against enterotoxins of Escherichia coli and Vibrio cholerae.

Morgan DR, Sellin J, Gutierrez L, DuPont HL, Wood LV.

Infect Immun. 1985 Jun;48(3):754-8.

49.

A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli.

Mathewson JJ, Johnson PC, DuPont HL, Morgan DR, Thornton SA, Wood LV, Ericsson CD.

J Infect Dis. 1985 Mar;151(3):471-5.

PMID:
3882849
50.

Efficacy of bicozamycin in preventing traveler's diarrhea.

Ericsson CD, DuPont HL, Galindo E, Mathewson JJ, Morgan DR, Wood LV, Mendiola J.

Gastroenterology. 1985 Feb;88(2):473-7.

PMID:
3965336

Supplemental Content

Support Center